Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

LianBio Signs $147 Million Deal for Long-Term Rhinosinusitis Product from Lyra

publication date: Jun 2, 2021

LianBio acquired China rights to a long-term treatment for chronic rhinosinusitis (CRS) from Lyra Therapeutics in an agreement worth up to $147 million. LYR-210 combines a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex to provide six-months of therapy. Lyra positions the product, which is in late-stage trials, as an alternative to surgery for people with CRS that does not respond to other drugs. Formed last year, LianBio is a China in-licensing company that is headquartered in Shanghai and Princeton. More details....

Stock Symbol: (NSDQ: LYRA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.